Table 2.
Incidence rates (95% CI) and hazard ratios (95% CI) of venous thromboembolism in relation to plasma galectin‐3 concentration, ARIC, 1996‐2013
| Galectin‐3 Quintiles (ng/mL) | |||||||
|---|---|---|---|---|---|---|---|
| Q1 (4.4‐11.4) | Q2 (11.5‐13.3) | Q3 (13.4‐15.1) | Q4 (15.2‐17.5) | Q5 (17.6‐114.0) | P‐trend | Per 1‐SD increment in log galectin‐3 | |
| VTE, n | 58 | 71 | 63 | 89 | 108 | – | – |
| Person‐years | 26075 | 26803 | 25600 | 24928 | 23676 | – | – |
| Incidence ratea | 2.2 (1.7‐2.9) | 2.6 (2.1‐3.3) | 2.5 (1.9‐3.2) | 3.6 (2.9‐4.4) | 4.6 (3.8‐5.5) | – | – |
| Model 1 | 1 (Referent) | 1.19 (0.84‐1.69) | 1.11 (0.78‐1.58) | 1.62 (1.17‐2.26) | 2.11 (1.54‐2.91) | <.0001 | 1.31 (1.19‐1.44) |
| Model 2 | 1 (Referent) | 1.15 (0.81‐1.63) | 1.04 (0.72‐1.49) | 1.48 (1.06‐2.08) | 1.81 (1.30‐2.54) | <.0001 | 1.24 (1.12‐1.38) |
| Model 3 | 1 (Referent) | 1.13 (0.80‐1.61) | 1.00 (0.70‐1.43) | 1.36 (0.96‐1.91) | 1.55 (1.09‐2.19) | .005 | 1.17 (1.04‐1.31) |
| Model 4 | 1 (Referent) | 1.09 (0.77‐1.55) | 0.95 (0.66‐1.37) | 1.27 (0.90‐1.79) | 1.37 (0.96‐1.94) | 0.04 | 1.09 (0.98‐1.22) |
ARIC, Atherosclerosis Risk in Communities study; BMI, body mass index; CI, confidence interval; CRP, C‐reactive protein; eGFR, estimated glomerular filtration rate; NT‐proBNP, N‐terminal pro–B‐type natriuretic peptide; SD, standard deviation; VTE, venous thromboembolism.
SD log galectin‐3=0.27 log ng/mL.
Model 1: crude model.
Model 2: adjusted for age (continuous), sex (female, male), and race (white, black).
Model 3: Model 2 plus diabetes (yes, no), BMI (continuous), and eGFR (continuous).
Model 4: Model 3 plus log CRP (continuous), log Troponin T (continuous), and log NT‐proBNP (continuous).
Incidence rate is unadjusted and per 1000 person‐years.